Your AI-Trained Oncology Knowledge Connection!

The Evolving Treatment Paradigm in Multiple Myeloma: Recent Updates : Episode 15

Video

August 8, 2023

CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond

Author(s):

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB

Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.

EP: 1.What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?

EP: 2.NDMM: Identifying Patient and Disease Factors to Select Appropriate Therapy

EP: 3.Induction Therapy Regimens for Transplant-Eligible NDMM

EP: 4.Impact of Risk Status on Treatment Pathways in Newly Diagnosed Multiple Myeloma

EP: 5.Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma

EP: 6.Determining Frailty in Patients With Newly Diagnosed Multiple Myeloma

EP: 7.Treatment Duration in Patients With Newly Diagnosed Multiple Myeloma

EP: 8.Patient Scenario: Treatment Options in MM at First Relapse

EP: 9.Factors in Selecting Therapy at First Relapse in Multiple Myeloma

EP: 10.Patient Scenario: Bispecifics in MM After Multiple Prior Lines of Therapy

EP: 11.Multiple Myeloma: Sequencing Novel Therapies in Later Lines of Treatment

EP: 12.Bispecifics in Multiple Myeloma: Dosing and Transition of Care

EP: 13.Combination Strategies With Bispecifics in Multiple Myeloma

EP: 14.Bispecifics in Multiple Myeloma: Adverse Event Management

Now Viewing

EP: 15.CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond

EP: 16.Multiple Myeloma: Unmet Needs and Future Directions in Care

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

May 15th 2025 - May 16th 2026

online-activity

Video

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

May 15th 2025 - May 16th 2026

online-activity

Video

(CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

May 15th 2025 - May 16th 2026

online-activity

Latest Conference Coverage

T-DM1 Plus Palbociclib Displays Activity in HER2+ Metastatic Breast Cancer

EL1SSAR Data Shed Light on Leveraging Atezolizumab Plus Nab-Paclitaxel in PD-L1+ TNBC

Pretreatment ctDNA Status Is Associated With Distant Recurrent-Free Survival in Early Breast Cancer

Zanidatamab/Chemotherapy Yields Responses and Is Safe in HER2-Expressing Metastatic Breast Cancer

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond

EP: 1.What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?

EP: 2.NDMM: Identifying Patient and Disease Factors to Select Appropriate Therapy

EP: 3.Induction Therapy Regimens for Transplant-Eligible NDMM

EP: 4.Impact of Risk Status on Treatment Pathways in Newly Diagnosed Multiple Myeloma

EP: 5.Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma

EP: 6.Determining Frailty in Patients With Newly Diagnosed Multiple Myeloma

EP: 7.Treatment Duration in Patients With Newly Diagnosed Multiple Myeloma

EP: 8.Patient Scenario: Treatment Options in MM at First Relapse

EP: 9.Factors in Selecting Therapy at First Relapse in Multiple Myeloma

EP: 10.Patient Scenario: Bispecifics in MM After Multiple Prior Lines of Therapy

EP: 11.Multiple Myeloma: Sequencing Novel Therapies in Later Lines of Treatment

EP: 12.Bispecifics in Multiple Myeloma: Dosing and Transition of Care

EP: 13.Combination Strategies With Bispecifics in Multiple Myeloma

EP: 14.Bispecifics in Multiple Myeloma: Adverse Event Management

EP: 15.CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond

EP: 16.Multiple Myeloma: Unmet Needs and Future Directions in Care

Newsletter

Latest CME

(CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Indiana

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Louisiana

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

(CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Indiana

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Louisiana

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

(CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Indiana

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Louisiana

Latest Conference Coverage